Ki-67和BRAF基因突变与甲状腺乳头状癌侵袭性关系的研究进展

doi:10.13481/j.1671-587x.20160641

[1] Nagar S,Aschebrook-Kilfoy b,Kaplan EL,et al.Age of diagnosing physician impacts the incidence of thyroid cancer in a population[J].Cancer Cause Control,2014,25(12):1627-1634.
[2] Tang C,Yang L,Wang N,et al.High expression of GPER1,EGFR and CXCR1 is associated with lymph node metastasis in papillary thyroid carcinoma[J].Int J Clin Exp Pathol,2014,7(6):3213-3223.
[3] Davies L,Welch HG.Current Thymid Cancer Trends in the United States[J].JAMA Otolaryngol Head Neck Surg,2014,140(4):317-322.
[4] Liu Z,Xun X,Wang Y,et al.MRI and ultrasonography detection of cervical lymph node metastases in differentiated thyroid carcinoma before reoperation[J].Am J Transl Res,2014,6(2):147-154.
[5] Huang DP,Ye XH,Xiang YQ,et al.Thymectomy in central lymph node dissection for papillary thyroid cancer[J].Int J Clin Exp Med,2014,7(4):1135-1139.
[6] Montero PH,Ibrahimpasic T,Nixon IJ,et al.Thyroid metastasectomy[J].J Surg Oncol,2014,109(1):36-41.
[7] Cho SY,Lee TH,Ku YH,et al.Central lymph node metastasis in papillary microcarcinoma can be stratified according to the number,the size of metastatic foci,and the presence of desmoplasia[J].Surgery,2014,157(1):111-118.
[8] Liu FH,Kuo SF,Hsueh C,et al.Postoperative recurrence of papillary thyroid carcinoma with lymph node metastasis[J].Surg Oncol,2015,112(2):149-154.
[9] 徐亦熊,李学明,俞建平.BRAF基因突变和Ki-67蛋白表达与甲状腺乳头状癌的关系[J].南昌大学学报:医学版,2014,54(10):12-14.
[10] Jia Y,Yu Y,Li X,et al.Diagnostic value of BRAF(V600E) in difficult-to-diagnose thyroid nodules using fine-needle aspiration:systematic review and meta-analysis[J].Diagn Cytopathol,2014,42(1):94-101.
[11] Gerdes J,Schwab U,Lemke H,et al.Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation[J].Int J Cancer,1983,31(1):13-20.
[12] Duchrow M,Schluter C,Wohlenberg C,et al.Molecular characterization of the gene locus of the human cell proliferation-associated nuclear protein defined by monoclonal antibody Ki67[J].Cell Prolif,1996,29(1):1-12.
[13] 李刚强,濮亚斌.CD147和Ki-67在甲状腺乳头状癌中的表达及意义[J].现代肿瘤医学,2015(13):1818-1820.
[14] Pillai K,Pourgholami MH,Chua TC,et al.Prognostic significance of Ki67 expression in malignant peritoneal mesothelioma[J].Am J Clin Oncol,2015,38(4):388-394.
[15] 郭民英,邢永川,陈卫伶,等.Bcl-2、p53和Ki-67在甲状腺癌中的表达及其临床意义的研究[J].现代肿瘤医学,2014,22(6):1294-1297.
[16] Koc N,Sahin D,Ayas S.Reevaluation of negative cone biopsy results after a positive cervical biopsy finding[J].Low Genit Tract Dis,2013,17(2):154-159.
[17] Denkert C,Loibl S,Muller BM,et al.Ki-67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies:a translational investigation in the neoadjuvant GeparTrio trial[J].Ann Oncol,2013,24(11):2786-2793.
[18] Ahn HK,Jung M,Ha SY,et al.Clinical significance of Ki-67 and p53 expression in curatively resected non-small cell lung cancer[J].Tumor Biol,2014,35(6):5735-5740.
[19] Pervez S,Haroon S,Awan D.Ki-67 Labeling indices in ‘Classic’ versus ‘Blastoid’ mantle cell lymphomas-proposed cutoff values for routine diagnostic workup[J].Asian Pac J Cancer P,2015,16(15):6591-6594.
[20] Aiad H A,Bashandy MA,Abdou AG,et al.Significance of AgNORs and Ki-67 proliferative markers in differential diagnosis of thyroid lesions[J].Pathol Oncol Res,2013,19(2):167.
[21] Pujani M,Arora B,Pujani M,et al.Role of Ki-67 as a proliferative marker in lesions of thyroid[J].Indian J Cancer,2010,47(3):304-307.
[22] Song Q,Wang D,Yi L,et al.Diagnostic significance of CK19,TG,Ki67 and galectin-3 expression for papillary thyroid carcinoma in the northeastern region of China[J].Diagn Pathol,2011,6(1):126.
[23] Ranjbari N,Rahin F.The Ki-67/MIB-1 index level and recurrence of PTC[J].Med Hypotheses,2013,80(3):311-314.
[24] 万汉锋,张彬,王勇,等.甲状腺结节BRAF V600E突变检测的临床意义[J].中华耳鼻咽喉头颈外科杂志,2014,49(6):468-472.
[25] Ball DW,Jin N,Xue P,et al.Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer[J].Int J Endo Oncol,2015,2(2):135-142.
[26] Galrgo A,Sodr6 A,Camargo R,et al.Methylation levels of sodiumiodide sympoger(NIS) promoter in benign and malignant thyroid tumors with reduced NIS expression[J].Endocrine,2013,43(1):225-229.
[27] Riescoeizaguirre G,Rodríguez I,De IVA,et al.The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer[J].Cancer Res,2009,69(21):8317-8325.
[28] Xing M,Alzahrani AS,Carson KA,et al.Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer[J].JAMA,2013,309(14):1493-1501.
[29] Li F,Chen G,Sheng C,et al.BRAFV600E mutation in papillary thyroid microcarcinoma:a meta-analysis[J].Endocr Relat Cancer,2015,22(2):159-168.
[30] Oh WJ,Lee YS,Cho U,et al.Classic papillary thyroid carcinoma with tall cell features and tall cell variant have similar clinicopathologic features[J].Korean J Pathol,2014,48(3):201-208.
[31] Pyo JS,Sohn JH,Kang G.BRAF immunohistochemistry using clone VE1 is strongly concordant with BRAF V600E mutation test in papillary thyroid carcinoma[J].Endocr Pathol,2015,36(3):211-217.
[32] Zhang B,Liu S,Zhang Z,et al.Analysis of BRAF (V600E) mutation and DNA methylation improves the diagnostics of thyroid fine needle aspiration biopsies[J].Diagn Pathol,2014(9):45.
[33] Adeniran AJ,Theoharis C,Hui P,et al.Reflex BRAF testing in thyroid fine-needle aspiration biopsy with equivocal and positive interpretation:a prospective study[J].Thyroid,2011,21(7):717-723.
[34] Xing M,Alzahrani AS,Carson KA,et al.Association between BRAF V600E mutation and recurrence of papillary thyroid cancer[J].Clini Oncol,2015,33(1):42-50.
[35] Puxeddu E,Filetti S. BRAF mutation assessment in papillary thyroid cancer:Are we ready to use it in clinical practice?[J].Endocrine,2014,45(3):341-343.
[36] Borrelli N,Clara Ugolini MD,Giannini R,et al.Role of gene expression profiling in defining indeterminate thyroid nodules in addition to BRAF analysis[J].Cancer Cytopathol,2016,124(5):340-349.

Progress research on relationship between Ki-67 and BRAF gene mutation and invasiveness of papillary thyroid carcinoma

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Comments

Recommended 0

[1]	. Research progress in thyroid cancer related genes and their applications in clinical diagnosis [J]. Journal of Jilin University Medicine Edition, 2018, 44(04): 880-885.
[2]	ZHAO Zhiyan, SHENG Jindong, LIU Baoguo. Risk factors of malignant thyroid neoplasms and papillary thyroid cancer level Ⅵ lymph node metastasis [J]. Journal of Jilin University Medicine Edition, 2017, 43(02): 334-338.
[3]	ZHAO Min-xue，LI Bai-wen，ZHU Lin，YE Hong-shan，TIAN Xiao-feng，WEI Liang，CAO Hong. Detection of miR-21 expression levels in carcinoma tissue and serum of patients with papillary thyroid carcinoma and its significance [J]. Journal of Jilin University Medicine Edition, 2014, 40(06): 1237-1240.
[4]	SUN Qin-nuan，LI Dong-mei，YU Hui-ling，MA Hong-xi. Expressions of inflammatory factors in thyroid papillary carcinoma tissue and their clinical significances [J]. Journal of Jilin University Medicine Edition, 2014, 40(06): 1261-1265.
[5]	WU Wen-fang,QIU Jin-xu,LU Li-min,YANG Dong-yan . Characteristics of ultrasound imaging of thyroid papillary carcinoma complicated with cervical lymph node tuberculosis [J]. Journal of Jilin University Medicine Edition, 2014, 40(04): 895-897.
[6]	WANG Hai-ying,JIN Mei-shan,ZHANG Xin-mu,TIAN Zhuang,ZOU Ya-bin,GAO Jing-na,DUAN Xiu-mei,WANG Yin-ping. Expressions of survivin,galectin-3 and TPO in papillary  thyroid microcarcinoma tissue and their clinical significances  [J]. Journal of Jilin University Medicine Edition, 2014, 40(01): 150-153.
[7]	. Advanced research on relationship between iodine intake and thyriod cancer [J]. Journal of Jilin University Medicine Edition, 2013, 39(4): 847-850.
[8]	WANG Chong，LIU Xiao-li，SHI Jie-ping，WU Yan-hua，WANG Shi-bing，YU Ya-qin，SUN Hui. Association analysis between RET gene polymorphism and papillary thyroid carcinoma [J]. Journal of Jilin University Medicine Edition, 2013, 39(2): 322-325.
[9]	HE Meng-zi,ZHAO Yin-long,LIU Xiao-dong,MA Shu-mei,LIU Xin. Screening and prediction of differential expression miRNA and their target genes in papillary thyroid carcinoma tissue [J]. Journal of Jilin University Medicine Edition, 2013, 39(1): 99-103.
[10]	SUN Ya-dong, ZHANG Jing-bin, YANG Le,MA Yan, JIANG Chun-hao,DI Jun . Expression \|of EG-1 in human thyroid papillary carcinoma tissue detected by real-time quantitative  PCR and its clinical significance [J]. J4, 2012, 38(5): 981-984.
[11]	LI Xin-bai,MENG Xian-ying,WANG Guang-yi,ZHANG Qiang,LI Qun. Inhibitory effects of celecoxib on \|expressions of VEGF  \|and　 MMP-9 in human medullary thyroid TT cells and their mechanisms [J]. J4, 2012, 38(3): 543-546.
[12]	NIU Chun-bo\|WANG Li-ping\|WANG Xue-mei\|CUI Ya-nan\|JIA Fei-yong\|ZHANG Guang. Application of Galectin-3 and CK19 expressions in pathological diagnosis of \|thyroid puncture biopsy [J]. J4, 2012, 38(2): 312-314.
[13]	LI Xin-bai,LIU Huan-qiu,MENG Xian-ying,YUAN Tong,HAN Wei,TONG Ti,MA Hai-chun. Application of dexmedetomidine combined with fibreoptic bronchoscope for tracheal intubation in difficult airways caused by huge goiter [J]. J4, 2012, 38(2): 328-332.
[14]	YU Peng,GONG Feng-ling,LIANG Yong-ping,WANG Rong-fu,ZHANG Jian-hua. Analysis on correlation of thyroglobulin with 131-iodine whole body scan in differentiated thyroid carcinoma patientsafter thyroid ablation [J]. J4, 2011, 37(4): 691-694.
[15]	HUA Te-bo,MENG Xian-ying,WANG Guang-yi,ZHANG Qiang,REN Jiang,LIU Jia,CHEN Guang. Detection \|of \|COX-2\|MMP-9\|VEGF and RET in thyroid tissues and significances in primary diagnosis of papillary thyroid carcinoma [J]. J4, 2011, 37(4): 712-717.